Company Description
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally.
It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.
The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.
In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot.
Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application.
Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments.
The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors.
Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
| Country | United States |
| Founded | 2010 |
| IPO Date | Oct 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 574 |
| CEO | Albert DaCosta |
Contact Details
Address: 14445 Grasslands Drive Englewood, Colorado 80112 United States | |
| Phone | 720-912-1332 |
| Website | paragon28.com |
Stock Details
| Ticker Symbol | FNA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001531978 |
| CUSIP Number | 69913P105 |
| ISIN Number | US69913P1057 |
| Employer ID | 27-3170186 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Albert DaCosta | Co-Founder, Chairman, President and Chief Executive Officer |
| Kristina Wright | Independent Interim Chief Financial Officer and Director |
| Robert S. McCormack J.D. | General Counsel and Secretary |
| Matthew Jarboe | Chief Commercial Officer |
| Andrew James Hill | Executive Vice President of Research and Development |
| Jeff Sears | Vice President of Operations |
| Erik E Mickelson | Chief Accounting Officer and Controller |
| Matt Brinckman | Senior Vice President of Strategy and Investor Relations |
| Michelle Missal | Vice President and Chief Compliance Officer |
| John Shumaker | Executive Vice President of Sales - U.S. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 8, 2024 | SCHEDULE 13G/A | Filing |
| Mar 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |